Envista Holdings Corp logo

Envista Holdings Corp

NVST

NYSEHealthcareMedical - Instruments & Supplies

Regular session

$27.33

+$0.13 · +0.48%

Aug 24, 12:08 PM ET

NVST company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

80

Undervalued

Momentum

55

Neutral

Sentiment

70

Bullish

Risk resilience

69

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Paul A. Keel
Listed since
Sep 18, 2019
Employees
12,000

Market position

Day range

Current $27.33

52-week range

Current $27.33

Open
$27.305
Previous close
$27.20
Volume
387.43K
0.13× average
Average volume
3.08M
Average daily volume
Market cap
4.45B USD
Beta
0.86
Market reference 1
50-day average
$26.8086
+1.94% above average
200-day average
$24.9217
+9.66% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.03B USD
P/E (TTM)
46.32×
P/B (TTM)
1,438,327.54×
P/S (TTM)
1.56×
EV / EBITDA
12.23×
Earnings yield
1.29%
Free cash flow yield
6.32%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
55.50%
Operating margin
9.92%
Net margin
3.33%
Return on equity
1.51%
Return on assets
0.83%
Return on invested capital
1.23%

Financial health

Debt / equity
0.52×
Current ratio
2.38×
Altman Z-score
1,714,045.15
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends69%27%-14%-55%Gross margin, FY2021: 58.29%Gross margin, FY2022: 57.93%Gross margin, FY2023: 56.52%Gross margin, FY2024: 55.43%Gross margin, FY2025: 55.02%Operating margin, FY2021: 12.20%Operating margin, FY2022: 12.42%Operating margin, FY2023: 1.23%Operating margin, FY2024: -41.35%Operating margin, FY2025: 8.30%Net margin, FY2021: 13.57%Net margin, FY2022: 9.46%Net margin, FY2023: -3.90%Net margin, FY2024: -44.56%Net margin, FY2025: 1.73%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 58.29%. Gross margin FY2022 57.93%. Gross margin FY2023 56.52%. Gross margin FY2024 55.43%. Gross margin FY2025 55.02%. Operating margin FY2021 12.20%. Operating margin FY2022 12.42%. Operating margin FY2023 1.23%. Operating margin FY2024 -41.35%. Operating margin FY2025 8.30%. Net margin FY2021 13.57%. Net margin FY2022 9.46%. Net margin FY2023 -3.90%. Net margin FY2024 -44.56%. Net margin FY2025 1.73%.

Income trends

Revenue

2.72B USD+8.32%

Operating income

225.7M USD+1.26B USD

Net income

47M USD+1.17B USD
Income trends across reported periods3.1B USD1.57B USD32.83M USD−1.5B USDRevenue, FY2021: 2.51B USDRevenue, FY2022: 2.57B USDRevenue, FY2023: 2.57B USDRevenue, FY2024: 2.51B USDRevenue, FY2025: 2.72B USDOperating income, FY2021: 306.2M USDOperating income, FY2022: 319.2M USDOperating income, FY2023: 31.5M USDOperating income, FY2024: −1.04B USDOperating income, FY2025: 225.7M USDNet income, FY2021: 340.5M USDNet income, FY2022: 243.1M USDNet income, FY2023: −100.2M USDNet income, FY2024: −1.12B USDNet income, FY2025: 47M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.51B USD. Revenue FY2022 2.57B USD. Revenue FY2023 2.57B USD. Revenue FY2024 2.51B USD. Revenue FY2025 2.72B USD. Operating income FY2021 306.2M USD. Operating income FY2022 319.2M USD. Operating income FY2023 31.5M USD. Operating income FY2024 −1.04B USD. Operating income FY2025 225.7M USD. Net income FY2021 340.5M USD. Net income FY2022 243.1M USD. Net income FY2023 −100.2M USD. Net income FY2024 −1.12B USD. Net income FY2025 47M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.72B USD2.51B USD2.57B USD2.57B USD2.51B USD
Cost of goods sold1.22B USD1.12B USD1.12B USD1.08B USD1.05B USD
Gross profit1.5B USD1.39B USD1.45B USD1.49B USD1.46B USD
Research and development114M USD99.1M USD93.8M USD100.1M USD100.5M USD
Selling, general, and administrative1.16B USD1.14B USD1.03B USD1.03B USD989.5M USD
Operating expenses1.27B USD2.43B USD1.42B USD1.17B USD1.16B USD
Interest expense36.6M USD46.4M USD63.4M USD38.4M USD54.1M USD
Depreciation and amortization116M USD123.1M USD135.6M USD137.8M USD123.6M USD
Operating income225.7M USD−1.04B USD31.5M USD319.2M USD306.2M USD
Net income47M USD−1.12B USD−100.2M USD243.1M USD340.5M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+4.93%
11 comparable reports
Latest EPS result
0.41
Estimate 0.34 · Beat by 22.28%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.450.360.260.17Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 0.24, estimate 0.23, surprise +4.35%, Beat. Q2 2025, reported May 1, 2025: actual 0.24, estimate 0.2, surprise +20.00%, Beat. Q3 2025, reported Jul 31, 2025: actual 0.26, estimate 0.24, surprise +8.33%, Beat. Q4 2025, reported Oct 29, 2025: actual 0.32, estimate 0.27, surprise +18.52%, Beat. Q1 2026, reported Feb 5, 2026: actual 0.38, estimate 0.32, surprise +18.75%, Beat. Q2 2026, reported May 6, 2026: actual 0.36, estimate 0.31, surprise +16.13%, Beat. Q3 2026, reported Aug 5, 2026: actual 0.41, estimate 0.335, surprise +22.28%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.36, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates780.62M716.04M651.46M586.88MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 652.9M USD, estimate 645.88M USD, surprise +1.09%, Beat. Q2 2025, reported May 1, 2025: actual 616.9M USD, estimate 635.74M USD, surprise -2.96%, Miss. Q3 2025, reported Jul 31, 2025: actual 682.1M USD, estimate 642.55M USD, surprise +6.16%, Beat. Q4 2025, reported Oct 29, 2025: actual 669.9M USD, estimate 680.25M USD, surprise -1.52%, Miss. Q1 2026, reported Feb 5, 2026: actual 750.6M USD, estimate 679.98M USD, surprise +10.39%, Beat. Q2 2026, reported May 6, 2026: actual 705.5M USD, estimate 680.03M USD, surprise +3.74%, Beat. Q3 2026, reported Aug 5, 2026: actual 730.5M USD, estimate 716.11M USD, surprise +2.01%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 695.87M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$29.14

6.62% upside
Past 12 months12-month forecast

Price history unavailable

High $34.00Average $29.14Low $23.00

NVST peers

Continue in GoAI

Research NVST

research.disclaimer